Improved sensitivity of a multi-analyte early detection test based on mutation, methylation, aneuploidy, and protein biomarkers


Exact Sciences Corporation, Madison, WI     * Corresponding Author: fdiehl@exactsciences.com

Evaluation of an overarching multi-analyte classifier that combines detection of clinically-actionable prostate cancers. First, an optimal threshold for total prostate-specific antigen (PSA) was defined to reduce overdiagnosis. Second, the results from a case-control feasibility study including two changes. First, 127 samples from the test set that were previously classified as negative were reclassified as positive. Second, the 3-Biomarker LR classifier was combined with an OR-logic classifier via OR-logic. The test performance of both biomarker combinations is shown in Table 1. Improved sensitivity of a multi-analyte early detection test based on mutation, methylation, aneuploidy, and protein biomarkers...